Treatment of venous thromboembolism: Evaluation of low molecular weight heparins;Le traitement de la maladie thromboembolique veineuse: Bilan et place des heparines de bas poids moleculaire

Sang Thrombose Vaisseaux

Volumn 10, Issue 7, 1998, Pages 431-438

  Kher, A ^a   Fiessinger, J N ^b  

^a Euthémis ^*

^b HÔPITAL BROUSSAIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVITAMIN K; BLOOD CLOTTING FACTOR 10A INHIBITOR; DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; TINZAPARIN;

BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; HUMAN; LUNG EMBOLISM; RANDOMIZED CONTROLLED TRIAL; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOEMBOLISM;

EID: 0031688729     PISSN: 09997385     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Barrit D, Jordan S. Anticoagulant drugs in the treatment of pulmonary embolism : a controlled clinical trial. Lancet 1960 ; I : 143-50.
2. Brandjes D, Heijboer H, Buller H, et al. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal vein thrombosis. N Engl J Med 1992 ; 327 : 1485-9.
3. Samama MM, Kher A. Le traitement des thromboses veineuses profondes constituées par les héparines de bas poids moléculaire (HBPM). Sang Thromb Vaiss 1989 ; 1 : 353-7.
4. Ninet J, Coppéré B, Girard-Madoux MH, et al. Les héparines de bas poids moléculaire ontelles une place dans le traitement curatif des thromboses veineuses prodondes ? Sang Thromb Vaiss 1992 ; 4 : 385-93.
5. Alhenc-Gelas M, Jestin-Le Guernic C, Vitoux JF, Kher A, Atach M, Fiessinger JN. Adjusted versus fixed doses of the low-molecular-weight heparin fragmin in the treatment of deep vein thrombosis. Thromb Haemost 1994 ; 71 : 698-702.
6. Sieghbahn A, Hassan Y, Boberg J, et al. Subcutaneous treatment of deep venous thrombosis with low molecular weight heparin. A dose finding study with LMWH-Novo. Thromb Res 1989 ; 55 : 767-78.
7. Holmström M, Berglund MC, Granqvist S, et al. Fragmin once or twice daily subcutaneously in the treatment of deep venous thrombosis of the leg. Thromb Res 1992 ; 67 : 49-55.
8. Hull RD, Raskob GL, Pineo GF, et al. Subcutaneous low molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992 ; 326 : 975-82.
9. Lindmarker P, Holmström M, Granqvist S, Johnsson H, Lockner D. Comparison of once-daily subcutaneous fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thromb Haemost 1994 ; 72 : 186-90.
10. Fiessinger JN, Lopez-Fernandez M, Gatterer E, et al. Once-daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of deep vein thrombosis. Thromb Haemost 1996 ; 76 : 195-9
11. Luomanmäki K, Granqvist S, Hallert C, et al. A multicentre comparison of once-daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosis. J Intern Med 1996 ; 240 : 85-92.
12. Charbonnier BA, Fiessinger IN, Banga JD, et al. Comparison of a once daily with a twice daily subcutaneous low molecular weight heparin regimen in the treatment of deep vein thrombosis. Thromb Haemost 1998 ; 79 : 897-901.
13. Spiro TE. The Enoxaparin Clinical Trial Group. A multicenter clinical trial comparing once- and twice-daily subcutaneous enoxaparin and intravenous heparin in the treatment of acute deep vein thrombosis Thromb Haemost 1997 (suppl.) : 373-3.
14. Levine MN, Gent M, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep vein thrombosis N Engl J Med 1996 ; 334 : 677-81
15. Koopman MMW, Prandoni P, Piovella F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med 1996 ; 334 : 682-7.
16. Lindmarker P, Holmström M and the Swedish Venous Thrombosis Dalteparin Trial Group. Use of low molecular weight heparin (dalteparin), once daily, for the treatment of deep vein thrombosis. A feasibility and health economic study in an outpatient setting. J Intern Med 1996 ; 240 : 395-401.
17. Albada J, Nieuwenhuis HK, Sixma JJ. Treatment of acute venous thromboembolism with low molecular weight heparin (fragmin). Results of a double-blind randomized study Circulation 1989 ; 80 : 935-40.
18. Warkentin TE, Levine M, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995 ; 332 : 1330-5.
19. Meyer G, Brenot F, Pacouret G, et al. Subcutaneous low-molecular-weight heparin fragmin versus intravenous unfractionated heparin in the treatment of acute non massive pulmonary embolism : an open randomized pilot study. Thromb Haemost 1995 ; 74 : 1432-5
20. Théry C, Simonneau G, Meyer G, et al. Randomized trial of subcutaneous low-molecular-weight heparin CY216 (Fraxiparine) compared with intravenous unfractionated heparin in the curative treatment of submassive pulmonary embolism. Circulation 1992 ; 85 : 1380-9.
21. Simonneau G, Sors H, Charbonnier B, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. N Engl J Med 1997 ; 337 : 663-9.
22. The Columbus Investigators. Low-molecular weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med 1997 ; 337 : 657-62.
23. Melissari E, Parker CJ, Wilson NV, et al. Use of low molecular weight heparin in pregnancy. Thromb Haemost 1992 ; 68 : 652-6.
24. Sturridge F, De Swiet M, Letsky E. The use of low molecular weight heparin for thromboprophylaxis in pregnancy. Br J Obst Gynec 1994 ; 101 : 69-71.
25. Wahlberg TB, Kher A. Low molecular weight heparin as thromboprophylaxis in pregnancy. A retrospective analysis from 14 european clinics. Haemostasis 1994 ; 24 : 55-6.
26. Leizorovicz A, Simonneau G, Decousus H. Comparison for efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis : a meta-analysis. Br Med J 1994 ; 309 : 299-304.
27. Lensing AW, Prins MH, Davidson BL, Hirsh J. Treatment of deep venous thrombosis with low-molecular-weight heparins - a meta-analysis. Arch Intern Med 1995 ; 155 : 601-7.
28. Siragusa S, Cosmi B, Piovella F, et al. Low-molecular-weight-heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism : results of a meta-analysis. Am J Med 1996 ; 100 : 269-77.
29. Pini M, Aiello S, Manotti C, et al. Low molecular weight heparin versus, warfarin in the prevention of recurrences after deep vein thrombosis. Thromb Haemost 1994 ; 72 : 191-7
30. Das SK, Cohen AT, Edmonson RA, Melissari E, Kakkar VV. Low-molecular-weight heparin versus warfarin for prevention of recurrent venous thromboembolism : a randomized trial. World J Surg 1996 ; 20 : 521-7.